Specialized Know-How and Capacity to Support Demand for Oncolytic Viruses

Published: 7 May 2020 Author: Stefan Beyer, Ph.D., Chief Executive Officer and Kai Lipinski, Ph.D., Chief Scientific Officer

Few CDMOs are capable of supporting biopharma companies advancing oncolytic virus (OV) therapies toward late-stage clinical trials. Vibalogics, however, is investing in new large-scale capacity and will be positioned to provide process development through late-stage and commercial manufacturing services from state-of-the-art facilities in both the United States and Germany.

Read more here.

We’re the ideal CDMO for your Virotherapy project

Get in touch


Looking for something different?

Vibalogics can assist you through a comprehensive service portfolio – ensuring success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.


What to read next

GMP Manufacturing of Oncolytic Viruses: Cr…

The oncolytic virus (OV) sector needs to overcome several challenges to bring transformative cancer th…

Time to Outsource Viral Vector Development

A fast-growing sector The outsourcing of process development, manufacturing, and analytical testing i…

Top Tips in Selecting your Viral Vector Partner

From cutting-edge therapies for deadly cancers, to developing effective vaccines, the viral vector spa…